A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.

Main Inclusion Criteria: * Have a Body Mass Index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive. * All females of childbearing potential must have a negative pregnancy test. * Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception. Main Exclusion Criteria: * History of any clinically important disease or disorder which may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Any clinically important illness, medical/major surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * Any clinically important abnormalities in clinical chemistry, haematology, urinalysis or vital signs. * Positive result for serum hepatitis B surface antigen, hepatitis C antibody, and HIV antibody * History of long QT syndrome or history of additional risk factors for QT prolongation - for example a family history of long QT syndrome or the use of concomitant medications known to prolong the QT/QTc interval. Any clinically significant abnormalities on 12-lead ECG at the Screening Visit, as judged by the investigator, including but…